RESUMO
Objective: This study aims to observe the clinical efficacies of hyper-early low-dose alteplase thrombolysis in treating acute ischemic stroke [AIS]
Methods: Two hundred twenty AIS patients were randomly divided into group A [90 cases], group B [90 cases], and group C [40 cases]. The National Institutes of Health Stroke Scale [NIHSS] scores, mRS score-evaluated prognosis, intracranial hemorrhage, and mortality of the three groups were observed before and after the treatment
Results: The NIHSS scores of the three groups were significantly reduced after the treatment [P<0.05], among which the NIHSS score of group A was the lowest [P<0.05]; and the difference between group B and C was not significant [P>0.05] The incidence of such complications as cerebral hemorrhage in the three groups was low, and there was no significant difference among the groups [P>0.05]. The modified Rankin Scale [mRS] scores of the three groups showed that group A had much better prognosis than group B and C, while the difference between group B and group C was not significant
Conclusions: The hyper-early low-dose alteplase thrombolysis was safe and effective in Acute ischemic stroke [AIS]